metaEvidence - overview


			DCR
hepatocell cancer (HCC) hepatocell cancer (HCC)
versus nivolumab alone
	nivolumab plus ipilimumab vs. nivolumab alone	1	-
versus placebo
	durvalumab plus bevacizumab vs. placebo	1	-
	pembrolizumab based treatment vs. placebo	1	-
versus sorafenib
	Tislelizumab vs. sorafenib	1	-
versus Standard of Care (SoC)
	sintilimab vs. Standard of Care (SoC)	1	-
mHCC - (neo)adjuvant (NA) metastatic/advanced hepatocellular cancer (mHCC) mHCC - (neo)adjuvant (NA)
versus nivolumab alone
	nivolumab plus ipilimumab vs. nivolumab alone	1	-
versus Standard of Care (SoC)
	atezolizumab plus bevacizumab vs. Standard of Care (SoC)	1	-
	sintilimab vs. Standard of Care (SoC)	1	-
mHCC - 1st line (L1) metastatic/advanced hepatocellular cancer (mHCC) mHCC - 1st line (L1)
versus lenvatinib
	pembrolizumab plus lenvatinib vs. lenvatinib	1	-
versus placebo
	durvalumab plus bevacizumab vs. placebo	1	-
versus sorafenib
	atezolizumab plus bevacizumab vs. sorafenib	1	-
	atezolizumab plus cabozantinib vs. sorafenib	1	-
	camrelizumab based treatment vs. sorafenib	1	-
	durvalumab plus tremelimumab vs. sorafenib	1	-
	nivolumab alone vs. sorafenib	1	-
	sintilimab vs. sorafenib	1	-
	Tislelizumab vs. sorafenib	1	-
mHCC - 2nd line (L2) metastatic/advanced hepatocellular cancer (mHCC) mHCC - 2nd line (L2)
versus placebo
	pembrolizumab alone vs. placebo	1
	pembrolizumab based treatment vs. placebo	1